-
MODELING FUTURE EPIDEMIOLOGICAL AND ECONOMIC BURDEN OF HIV IN BRAZIL: PROJECTION OF SUBSTANTIAL NEW INFECTIONS AND COSTS THROUGH TO 2034
Aug 11, 2026, 17:15 PM -
HAS FRANCE'S EARLY ACCESS SCHEME BECOME MORE SELECTIVE? EVIDENCE FROM TEMPORAL TRENDS IN EARLY ACCESS AND SUBSEQUENT ASMR RATINGS
Aug 11, 2026, 17:15 PM -
RETURN ON INVESTMENT OF ONE-TIME LIPOPROTEIN(A) TESTING FOR CARDIOVASCULAR RISK PREVENTION IN BULGARIA
Aug 11, 2026, 17:15 PM -
A NARRATIVE REVIEW AND PATIENT-REPORTED OUTCOME (PRO) LANDSCAPE ASSESSMENT TO INFORM THE DEVELOPMENT OF THE NOVEL SUICIDAL AND SELF-INJURIOUS BEHAVIOR SCALE (SASIBS)
Aug 11, 2026, 17:15 PM -
ASSOCIATION BETWEEN VASOMOTOR SYMPTOM RESPONSE AND EQ-5D IN WOMEN WITH BREAST CANCER EXPERIENCING MODERATE-TO-SEVERE VASOMOTOR SYMPTOMS CAUSED BY ADJUVANT ENDOCRINE THERAPY
Aug 11, 2026, 17:15 PM -
CLINICAL UTILITY OF ENHANCED LIVER FIBROSIS (ELF)-GUIDED REFERRAL STRATEGIES: A DECISION CURVE ANALYSIS IN US VETERANS
Aug 11, 2026, 17:15 PM -
CURRENT TREATMENT PATTERNS IN NON-METASTATIC MELANOMA IN THE MODERN TREATMENT ERA: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)-MEDICARE ANALYSIS
Aug 11, 2026, 17:15 PM -
MODELLED ESTIMATION OF DIRECT HEALTHCARE COSTS ATTRIBUTABLE TO OBESITY-RELATED COMORBIDITIES IN THE ENTITY OF REPUBLIKA SRPSKA
Aug 11, 2026, 17:15 PM -
MMR-MSI TESTING PATTERNS IN A REAL-WORLD CANADIAN SETTING: INSIGHTS FROM AN AI-ENABLED ANALYSIS
Aug 11, 2026, 17:15 PM -
STATE TRANSITION OR PARTITIONED SURVIVAL MODEL? MODEL SELECTION FRAMEWORKS FOR EARLY-STAGE ONCOLOGY
Aug 11, 2026, 17:15 PM -
LINKING PHARMACY CLAIMS AND EHR-DERIVED ANTHROPOMETRICS TO EVALUATE REAL-WORLD GLP-1 OUTCOMES IN OBESITY LEVERAGING NORSTELLALINQ EHR AND VITALS DATA
Aug 11, 2026, 17:15 PM -
NET-PRICE INFORMATION ASYMMETRY IN REIMBURSEMENT NEGOTIATION: AN ECONOMICALLY JUSTIFIABLE PRICE REFERENCE FRAMEWORK FOR ENTRANT THERAPIES
Aug 11, 2026, 17:15 PM -
BURDEN OF ILLNESS OF METACHROMATIC LEUKODYSTROPHY - AN AI ASSISTED TARGETED LITERATURE REVIEW
Aug 11, 2026, 17:15 PM -
REAL-WORLD USE OF GLP-1 RECEPTOR AGONISTS IN PORTUGUESE COMMUNITY PHARMACIES: THERAPEUTIC INDICATIONS, REIMBURSEMENT, AND ACCESS TO TREATMENT
Aug 11, 2026, 17:15 PM -
A GENERAL FRAMEWORK FOR IPD META-ANALYSIS OF COMPETING RISKS DATA WITH FLEXIBLE PARAMETRIC SURVIVAL MODELS: ESTIMATION, PREDICTION AND SOFTWARE
Aug 11, 2026, 17:15 PM -
THE HEALTH CARE RESOURCE UTILIZATION (HCRU) AND CLINICAL BURDEN OF HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN (HDFN) IN EUROPE - FINDINGS FROM A REAL-WORLD SURVEY
Aug 11, 2026, 17:15 PM -
SOCIETAL IMPACT OF A DISEASE - THE CASE OF HEMOPHILIA A. EVIDENCE FROM A DANISH NATIONAL REGISTER STUDY
Aug 11, 2026, 17:15 PM -
WHAT MATTERS BEYOND MODEL ARCHITECTURE? SPONSORSHIP, RISK EXTRAPOLATION, AND FAVOURABLE CONCLUSIONS IN EVALUATIONS OF NEWER TYPE 2 DIABETES THERAPIES
Aug 11, 2026, 17:15 PM -
REAL-WORLD TREATMENT PATTERNS AND LINE-TO-LINE TRANSITIONS IN MULTIPLE MYELOMA IN POLAND: A POLICY-ALIGNED ANALYSIS OF PUBLICLY AVAILABLE NATIONAL HEALTH FUND (NFZ) DATA
Aug 11, 2026, 17:15 PM -
IDENTIFYINGWHETHER COST OR CLINICAL OUTCOMES DRIVE HETEROGENEITY: THE COST-EFFECTIVENESS VARIABILITY INDEX (CEVI)
Aug 11, 2026, 17:15 PM
